Gilead Sciences, Inc.
GILD · Price history
Price at last available close
$159.08
+$6.87 (+4.51%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Gilead Sciences, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 6, 2026. A research update is not a new financial filing.
Who they are
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions.
How they make money
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines for life-threatening diseases. The company generates revenue primarily through the sale of its proprietary pharmaceutical products, focusing on areas such as HIV, viral hepatitis, oncology, and inflammatory diseases.
Products & services
Gilead provides a portfolio of medicines including Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo for HIV-1, as well as treatments for oncology and liver diseases.
Brands & revenue mix
HIV prevention and treatment medication.
Separate brand revenue is not available in this research.Source
Twice-yearly HIV prevention therapy.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Customer concentration
Gilead sells its products primarily to wholesalers, distributors, pharmacies, and government agencies. As of the fiscal year ended December 31, 2025, the company discloses that a significant portion of its revenue is derived from a limited number of large wholesalers.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company utilizes third-party contract manufacturers for the production of certain active pharmaceutical ingredients and finished drug products; specific supplier names are unnamed.Source
Competitors
Strengths
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Quarterly EPS turned negative at -8.45 versus 1.56 a year earlier.
Separate recurring operating losses from noncash or one-time charges, and check cash flow rather than interpreting negative EPS as a cash-outflow amount.
Quarterly net income turned from a profit to a loss versus the same quarter last year.
Identify the causes in the interim report and distinguish operating cash use from accounting charges. Prior profitability is not a guarantee of recovery.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
28
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
53
Fair
Financial Strength
66
Business Quality / Moat
38
Management
50
Growth Quality
32
Risk / Durability
83
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
30
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
35/100
Building Historical Record
Model Score 35/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Recent buyback activity is present
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for GILD
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can GILD maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is GILD's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is GILD's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for GILD to reach sustainable profitability?
- •What future growth or profitability would be needed to justify GILD's current valuation?
Essential Investment Snapshot
Wall Street Score
28
Opportunity Score
30
Market Cap
$197.25B
P/E Ratio
-57.3
EPS
$-2.60
52-Week High
$157.29
52-Week Low
$108.46
Beta
0.35
Analyst Target
$150.00
Shares Outstanding
1.25B
Total Revenue
$30.46B
Total Debt
$26.25B
Dividend Yield (TTM)
2.04%
Liquidation Value / Share
$9.36
Dividend / Share (TTM)
$3.25
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Building upward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for GILD
Detected from reported data — verify before acting.Dividend history reported
Dividend payments are recorded. Review the dates and regular/special classification below; past payments do not guarantee future dividends.
Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on GILD.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Strong market leadership in HIV treatment.
- +Robust R&D pipeline for transformative science.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Drug Manufacturers - General industry.
- −Intense competition and pricing pressure.
- −Regulatory and clinical trial failure risks.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
4 historical score records availablePrevious Score
27
Sep 28, 2026
Change
+0.1
points
Current Score
28
Oct 1, 2026
Category Changes
GILD increased 0.1 points because overall fundamentals improved.
Projected Score
Projected Score
23
Projected Change
-4.4 points
Preliminary comparable-period financial changes suggest decline of approximately 4.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$159.08
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.46B | $29.44B | $28.75B | $27.12B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $6.22B | $6.23B | $6.25B | $6.50B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $24.24B | $23.21B | $22.50B | $20.62B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $6.07B | $5.80B | $5.91B | $5.72B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $6.46B | $5.71B | $6.09B | $6.09B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $25.73B | $11.51B | $20.84B | $13.01B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $636.0M | $13.58B | $4.43B | $10.50B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$1.49B | $11.70B | $1.66B | $7.61B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $998.0M | $1.02B | $977.0M | $944.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$1.96B | $9.80B | $690.0M | $6.86B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $1.28B | $1.29B | $211.0M | $1.25B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$3.24B | $8.51B | $480.0M | $5.67B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-2.60 | $6.84 | $0.38 | $4.54 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 1.24B | 1.24B | 1.25B | 1.25B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 1.24B | 1.25B | 1.25B | 1.26B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$7.80B
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$8.45
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+5.2%
Cash Change
-38.2%
Margin Change
-162.2 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Weakened
- Margins contracted
- Cash position declined
- Debt increased
Potential Score Impact
Positive indicators included revenue growth. Pressure indicators included EPS growth, cash levels, debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 10.2%. EPS declined 641.7%. Cash declined 38.2%. Total debt increased 5.2%. Net income margin declined by 162.2 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
61
Smart Money
61
Number of Gurus
5
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Log in to view dividend history.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Drug Manufacturers - GeneralNews
Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Rumor Mill · GILD
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial